By Don Nico Forbes
Atara Biotherapeutics said the U.S. Food and Drug Administration placed a clinical hold on its active investigational new drug applications.
The biotechnology company said the FDA put a hold on its Ebvallo and ATA3219 programs due to compliance issues at a third-party manufacturing facility. Ebvallo is a treatment candidate for Epstein-Barr virus positive post-transplant lymphoproliferative disease, or EBV+PTLD. ATA3219 is a candidate for the treatment of non-Hodgkin's lymphoma and systemic lupus erythematosus.
The company noted that the issues don't affect its Fujifilm Diosynth Biotechnologies third-party facility in Thousand Oaks, Calif.
Atara added that it has agreed with the FDA upon necessary actions to release the clinical holds.
"We intend to work closely with the FDA to address these issues as expeditiously as possible," said Chief Executive Cokey Nguyen.
Shares of Atara fell 4.3% to $6.29 in premarket trading Tuesday.
Write to Don Nico Forbes at don.forbes@wsj.com
(END) Dow Jones Newswires
January 21, 2025 08:14 ET (13:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.